We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

108 hedge funds and large institutions have $377M invested in Aldeyra Therapeutics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more capital invested

Capital invested by funds: $155M → $377M (+$222M)

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

29% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 24

10% more funds holding

Funds holding: 98108 (+10)

9.43% more ownership

Funds ownership: 57.71%67.13% (+9.4%)

16% less call options, than puts

Call options by funds: $4.16M | Put options by funds: $4.95M

Holders
108
Holders Change
+10
Holders Change %
+10.2%
% of All Funds
1.9%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
32
Increased
31
Reduced
24
Closed
21
Calls
$4.16M
Puts
$4.95M
Net Calls
-$793K
Net Calls Change
+$701K
Name Holding Trade Value Shares
Change
Change in
Stake
Rafferty Asset Management
26
Rafferty Asset Management
New York
$1.94M +$1.88M +162,850 New
PAI
27
Palo Alto Investors
California
$1.91M
ECM
28
ExodusPoint Capital Management
New York
$1.86M +$195K +16,894 +12%
WMSA
29
Weiss Multi-Strategy Advisers
New York
$1.8M +$452K +39,231 +35%
WC
30
Woodstock Corp
Massachusetts
$1.76M
RA
31
Rovida Advisors
Florida
$1.54M +$1.5M +130,000 New
First Trust Advisors
32
First Trust Advisors
Illinois
$1.43M +$302K +26,195 +28%
EI
33
EAM Investors
California
$1.23M +$1.19M +103,191 New
Northern Trust
34
Northern Trust
Illinois
$1.07M +$194K +16,838 +23%
CSS
35
Cubist Systematic Strategies
Connecticut
$987K +$678K +58,860 +243%
Goldman Sachs
36
Goldman Sachs
New York
$899K +$377K +32,712 +76%
Wells Fargo
37
Wells Fargo
California
$887K +$776K +67,423 +930%
SFI
38
Susquehanna Fundamental Investments
Pennsylvania
$851K +$4.72K +410 +0.6%
AA
39
ALPS Advisors
Colorado
$834K +$12.2K +1,057 +2%
Stifel Financial
40
Stifel Financial
Missouri
$786K -$288K -25,010 -27%
HF
41
HRT Financial
New York
$778K -$618K -53,668 -45%
California Public Employees Retirement System
42
California Public Employees Retirement System
California
$766K
MFIM
43
Mesirow Financial Investment Management
Illinois
$756K -$12.3K -1,064 -2%
FMBTD
44
First Midwest Bank Trust Division
Illinois
$740K +$718K +62,331 New
Group One Trading
45
Group One Trading
Illinois
$719K +$697K +60,553 New
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$683K -$1.09M -94,687 -62%
PAM
47
Premier Asset Management
Illinois
$671K +$651K +56,505 New
Assenagon Asset Management
48
Assenagon Asset Management
Luxembourg
$639K -$2.48M -215,409 -80%
Barclays
49
Barclays
United Kingdom
$603K +$584K +50,745 New
UBS Group
50
UBS Group
Switzerland
$581K -$616K -53,473 -52%

ALDX Hedge Fund Activity: Q1 2021 in Review

108 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2021, worth a combined $377M — up 143% from $155M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ALDX positions and 21 closed out — a net gain of 11 holders — while 31 added to existing stakes and 24 trimmed.

The largest buyer was First Light Asset Management, opening a new position worth an estimated $30.2M. The largest seller was Citadel Advisors, cutting an estimated $12.3M.

  • 108 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2021, up from 98 in Q4 2020.
  • Funds reported $377M of Aldeyra Therapeutics stock for Q1 2021, up 143% quarter-over-quarter.
  • 32 funds opened new Aldeyra Therapeutics positions in Q1 2021 and 21 closed out, a net change of +11 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2021 was First Light Asset Management, an estimated $30.2M added.
  • The largest Aldeyra Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2021.